Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female between the age of 18 and 65 years and in good health having evidence of mid-substance unilateral, chronic Achilles tendinosis confirmed by ultrasound imaging.~2. Participant confirmation of symptoms of unilateral chronic Achilles tendinosis for at least 6 months~3. Completion of at least three months of physiotherapy for treatment of Achilles tendinosis at the study tendon as directed by a certified physiotherapist.~4. VISA-A score of less than 70 at Visit S1.~5. Willingness to provide written informed consent for participation in the study, attend all study visits and complete all procedures required by this protocol.~6. Fluent understanding of written and spoken English language~7. Females must either be post-menopausal for at least one year, surgically sterile, or, if of childbearing potential, using highly-effective methods of birth control during the study. This method of contraception must be used at least 4 weeks prior to screening (Visit S1) and during the entire duration of the clinical trial.~Exclusion Criteria:~1. Any prior therapeutic injections to the Achilles tendon to be studied (e.g., platelet-rich plasma, prolotherapy, dextrose, dry needling, etc) within 6 months of study Visit S1.~2. History of Achilles tendon surgery (either tendon)~3. Presence of enthesopathy or insertional tendinopathy in any tendons of the lower extremity, including Achilles tendons.~4. Presence of any medical condition that influences lower extremity function (e.g. osteoarthritis, presence of any peripheral nerve involvement, etc.)~5. Presence of seronegative arthropathies, diabetes mellitus (type I and II), elevated blood sugar, insertional arthropathies-psoriasis, iritis, inflammatory bowel syndrome, sacroiliitis, metabolic syndrome or positive test for human leukocyte antigen (HLA) B 27.~6. Any condition that, in the investigator's opinion would impact participant safety and/or a participant's ability to complete all study related procedures. (e.g., psychiatric illness, drug addiction, alcoholism, etc.)~7. Infection with hepatitis B or C, human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV) or syphilis~8. Participants diagnosed with cancer with or without chemotherapy treatment~9. Women who are pregnant or nursing~10. Ongoing or recent (within the previous 6 months) participation in a clinical research study.~11. Participants diagnosed having uncontrolled systemic diseases~12. Use of any medications not permitted in the study (see Excluded Medications)~13. Participants currently using other active treatments for tendinosis other than physiotherapy (e.g., acupuncture, trigger point therapy, chiropractic treatments, glyceryl trinitrate patches) during study or within 3 months prior to Visit 1~14. Unresolved litigation or insurance claims (e.g., Workers Compensation, WorkSafe BC, etc.) involving the Achilles tendinopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- RCT-01 (Type: EXPERIMENTAL): Cultured, autologous hair follicle cells suspended in cryomedium
- Placebo (Type: PLACEBO_COMPARATOR): cryomedium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues